目的：分析比较眼球钝挫伤引起的外伤性晶状体半脱位 I 期与 II 期行经巩膜人工晶状体睫状沟缝线固定术的治疗效果。方法：收集自 2015 年 1 月至 2016 年 12 月在汕头国际眼科中心因眼球钝挫伤所致外伤性晶状体不全脱位行 I 期和 II 期行经巩膜人工晶状体睫状沟缝线固定术的患者 29 例（29眼），其中 I 期 11 例（11眼）、II 期 18 例（18眼）。观察 2 组视力、眼压及并发症发生率。结果：随访 3 ~ 30 个月，I期组术后视力提高达 90.9%，II 期组达94.4%。I 期组术后前房炎性反应发生率明显高于 II 期组，差异有统计学意义（P < 0.05）。2 组长期随访未见远期并发症。结论：I 期与 II 期行人工晶状体睫状沟缝线固定术均是治疗外伤性晶状体半脱位的理想方法。与 I 期手术相比，II 期手术的前房炎性反应发生率较低。

Objective: To compare the safety and efficacy of primary and secondary implantation of suspension intraocular lens (IOLs) in eyes with traumatic lens subluxation after blunt ocular trauma. Methods: A total of 29 eyes of 29 cases with traumatic lens subluxation were collected and analyzed retrospectively. All cases underwent the transscleral ciliary sulcus fixation of IOLs from January 2015 to December 2016 in our hospital. IOLs were implanted primarily in 11 eyes and secondarily in 18 eyes. Visual acuity, intraocular pressure and complications were discussed. Results: Patients were followed up for 3–30 months. The postoperative best corrected visual acuity was improved by 90.9% in phase I group and 94.4% in phase II group. Short-term post-operative anterior chamber inflammation much higher in phase I group than phase II group. No long-term complications occurred in all cases. Conclusion: Primary or secondary ciliary sulcus fixation of IOLs is safe and effective method in eyes with traumatic lens dislocation.

目的：以光学相干断层扫描血管成像(optical coherence tomography angiography，OCTA)观察视网膜分支静脉阻塞(branch retinal vein occlusion，BRVO)抗血管内皮生长因子(vascular endothelial growth factor，VEGF)治疗前后的变化。方法：回顾性收集从2017年1月至2018年1 2月在汕头国际眼科中心的确诊为BRVO合并黄斑水肿的患者共3 1例3 2眼。患眼行玻璃体腔注射抗VEGF药物治疗，记录治疗前和治疗后1个月的最佳矫正视力(best corrected visual acuity，BCVA)，OCTA检查视网膜黄斑中心凹厚度(foveal macular thickness，FMT)、黄斑区血流密度。比较治疗前后各指标的变化。结果：治疗后BCVA较治疗前显著提高，差异有统计学意义(P<0.001)；FMT[(242.13±86.02) μm]较治疗前[(521.44±190.27) μm]明显下降，差异有统计学 意义(P<0.001)；中心凹浅层血流密度[(18.44±4.98)%]及中心凹旁浅层血流密度[(44.83±3.19)%]均较治疗前[(25.46±9.21)%，(46.06±5.25)%]相比明显下降，差异有统计学意义(P <0.001)。结论：玻璃体腔注射抗VEGF治疗BRVO合并黄斑水肿效果显著；OCTA能有效评价抗VEGF治疗BRVO合并黄斑水肿的临床疗效。

Objective: To evaluate the efficacy in patients with macular edema due to branch retinal vein occlusion (BRVO) treated with intravitreal anti-VEGF drug. Methods: In this retrospective study, 32 eyes of 31 patients with BRVO combined with macular edema at Joint Shantou international eye center of Shantou University and TheChinese University of Hong Kong during January 2017 to December 2018 were enrolled in this study. All the affected eyes received intravitreal anti-VEGF drug injections. BCVA (best corrective visual acuity) and optical coherence tomography angiography (OCTA) were performed before and one month after intravitreal anti-VEGF drug injections. Foveal macular thickness (FMT), macular blood flow density was measured in all eyes and compared. Results: The BCVA before therapy was (0.77±0.46) LogMAR and increased to (0.46±0.30) LogMAR in one month after therapy, which showed a statistical difference (P<0.001). The FMT, foveal superficial vascular plexus flow density and para foveal superficial vascular plexus flow density before therapy were (521.44±190.27) μm, (21.85±6.17)% and (46.29±2.70)%, respectively. The FMT, foveal superficial vascular plexus flow density and para foveal superficial vascular plexus flow density decreased to (242.13±86.02) μm, (18.40±5.18)% and (44.75±3.40)%, respectively. There was significant statistical difference for them (P<0.001). Conclusion: Intravitreal injection of anti-VEGF is effective in the treatment of BRVO combined with macular edema. OCTA can effectively evaluate the clinical efficacy of anti-VEGF in the treatment of BRVO combined with macular edema.